Mohamed Somaia, Rosenheck Robert, McEvoy Joseph, Swartz Marvin, Stroup Scott, Lieberman Jeffrey A
VA Connecticut Health Care System, 950 Campbell Avenue/182, West Haven, CT 06516, USA.
Schizophr Bull. 2009 Mar;35(2):336-46. doi: 10.1093/schbul/sbn067. Epub 2008 Jun 26.
We evaluated the cross-sectional and longitudinal association of measures of both insight and attitudes toward medication to outcomes that included psychopathology and community functioning.
Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) was a large 18-month follow-up study pharmacotherapy of people with schizophrenia. Insight was measured using the Insight and Treatment Attitudes Questionnaire and attitudes toward medication by the Drug Attitude Inventory. Widely known scales were used to assess symptoms of schizophrenia and depression and community functioning. Medication adherence was globally assessed by the treating psychiatrist using several sources of information. Bivariate correlations and mixed model regression analyses were used to test the relationship of insight and medication attitudes to outcomes at baseline and during the follow-up period. Regression models were used to evaluate the relationship between change in insight and medication attitudes and changes outcomes.
There was a significant relationship at baseline between insight and drug attitudes and symptoms of schizophrenia and depression, as well as with community functioning. Higher levels of insight at baseline were significantly associated with lower levels of schizophrenia symptoms at follow-up while more positive medication attitudes were significantly associated with both lower symptom levels and better community functioning. Change in insight scores over time was associated with declining schizophrenia symptoms but increasing levels of depression. Change toward more positive medication attitudes was associated, independently of changes in insight, with significant decreases in psychopathology, improvement in community functioning, and greater medication compliance.
Greater patient understanding of their illness and more positive attitudes toward medication may improve outcomes. Educational interventions that affect these attitudes may be an important part of psychosocial rehabilitation and/or recovery-oriented services.
我们评估了自知力和用药态度测量指标与包括精神病理学和社区功能在内的结局之间的横断面和纵向关联。
干预有效性临床抗精神病药物试验(CATIE)是一项针对精神分裂症患者进行药物治疗的为期18个月的大型随访研究。使用自知力与治疗态度问卷测量自知力,通过药物态度量表测量用药态度。采用广为人知的量表评估精神分裂症和抑郁症症状以及社区功能。治疗精神科医生综合多种信息来源对药物依从性进行整体评估。采用双变量相关性分析和混合模型回归分析来检验基线期和随访期自知力和用药态度与结局之间的关系。使用回归模型评估自知力和用药态度的变化与结局变化之间的关系。
在基线期,自知力和药物态度与精神分裂症和抑郁症症状以及社区功能之间存在显著关系。基线期自知力水平较高与随访期精神分裂症症状水平较低显著相关,而更积极的用药态度与较低的症状水平和更好的社区功能均显著相关。随着时间推移,自知力得分的变化与精神分裂症症状的减轻但抑郁症水平的升高相关。朝着更积极的用药态度转变,独立于自知力的变化,与精神病理学显著减轻、社区功能改善以及更高的药物依从性相关。
患者对自身疾病的更多了解和对药物更积极的态度可能改善结局。影响这些态度的教育干预可能是心理社会康复和/或以康复为导向的服务的重要组成部分。